Indication: Urothelial Cancer
A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy
Locally advanced or metastatic
Sub-indication: Locally Advanced or Metastatic Urothelial Cancer with previous Tx with CPI.
Line of Therapy: 2nd line, must have received CPI in locally advanced or metastatic setting. Cohort 1: previous tx with platinum in adjuvant or neoadjuvant setting. Cohort 2: Platinum naive or cisplatin ineligible due to ECOG 2, Hearing loss Grade 2, or CRCL < 60 ml/min.
Principal Investigator: Chandler Park, M.D.
Sponsor: Seattle Genetics, Inc
Email for more information: GU-NCIResearch@nortonhealthcare.org